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GENERAL INTRODUCTION 
Acetaminophen has been available as an over-the-counter analagesic 
and antipyretic in the United States since 1955. In addition to its 
role in headache, cough and cold relief, studies have substantiated the 
efficacy of acetaminophen (ACAP) in the treatment of pain associated 
with episiotomy, osteoarthritis and dentistry (1). The best known 
preparation of ACAP sold in the United States is Tylenol. In 1982, this 
product accounted for 35% of all over-the-counter analgesics marketed 
( 2 ) .  
When used in recommended dosages, ACAP is considered to be safe and 
effective (3). ACAP is metabolized in the liver primarily as 
glucuronide or sulfate conjugates. A small proportion of ACAP is 
oxidized via the microsomal cytochrome P-450 mixed function oxidase 
system, producing a toxic electrophilic metabolite, that can be 
inactivated by glutathione conjugation. If ACAP is taken in excessive 
dosages, a much larger proportion is metabolized to the toxic metabolite 
as the normal glucuronidation and sulfation pathways are overwhelmed. 
As glutathione is depleted by conjugation of the metabolite, more of the 
toxic metabolite becomes available for binding to hepatic macromolecules 
and thereby produces cellular necrosis. 
The potential for ACAP-induced liver necrosis, therefore, depends 
on several factors. These include the total quantity of ACAP ingested, 
the plasma levels of ACAP, the rate of elimination, the relative 
activity of the metabolic pathways of glucuronidation, sulfation, 
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oxidation by the cytochrome P-450 system, and the hepatic reduced 
glutathione (GSH) levels. The GSH level, rather than amount of enzyme, 
is usually the rate-limiting factor in GSH conjugations (4). 
The relative activity of the glucuronidation and sulfation may 
depend on the activity of the sulfotransferase and UDP-glucuronosyl 
transferase, and the availability of the cofactors, inorganic sulfate 
and UDP-glucuronic acid. The activities of the cytochrome P-450 mixed 
function oxidase system have been shown to be stimulated by microsomal 
enzyme inducers, including chronic ethanol ingestion and 
anticonvulsants. Increased ACAP-induced liver damage has been 
associated with chronic ethanol ingestion in laboratory animals and 
humans (5-11). As the activity of the mixed function oxidase system is 
increased, there may be greater production of the ACAP toxic metabolite 
and therefore greater glutathione depletion and increased 
hepatotoxicity. 
Studies in animals have shown that nutritional status can directly 
affect hepatic glutathione levels. The extent to which cysteine is 
available for incorporation into glutathione depends, in part, on the 
activity of the hepatic transsulfuration pathway by which the methionine 
sulfur can be donated to the carbon skeleton of serine to produce 
cysteine. The activity of this pathway is dependent on the supply of 
methionine and the requirement of methionine for protein synthesis and 
methylation by S-adenosyImethionine reactions. Diets deficient in 
methionine have been shown to decrease hepatic glutathione levels in 
rats (12,13). 
3 
The purpose of this study is to determine how dietary methionine 
deficiency and chronic ethanol consumption affect the metabolism of ACAP 
in mice. This will be achieved by determining how methionine inadequacy 
and ethanol ingestion influence the factors that are responsible for 
altering the potential of ACAP to cause liver necrosis. 
Explanation of Dissertation Format 
This manuscript has been arranged in an alternate dissertation 
format. It includes this general introduction, a general review of the 
literature, two papers for publication and a final summary and 
discussion. The first section has been published in Drug-Nutrient 
Interactions, Volume 3, pages 43-51, 1984. The data in Section I were 
generated after modification of procedures used in a preceding master's 
thesis. 
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GENERAL REVIEW OF LITERATURE 
Acetaminophen Metabolism 
Acetaminophen (N-acetyl-p-aminophenol, paracetamol), is a commonly 
used non-narcotic analgesic and antipyretic. It is rapidly absorbed 
from the gastrointestinal tract, reaching peak plasma concentrations 
within 30-90 minutes and having a half-life of 2-3 hours. ACAP is 
relatively lipid soluble and is distributed throughout most body fluids 
(Vd = 0.70 - 0.75 1/Kg). In humans, a clinically insignificant 
proportion is bound to plasma proteins. The pharmacology and toxicity 
of ACAP have been thoroughly reviewed recently (1-3). 
ACAP is metabolized primarily in the liver (Figure 1). In 
therapeutic doses, the"major pathways involve sulfation and 
glucuronidation with subsequent urinary excretion of the polar 
metabolites. A minor metabolic pathway for ACAP, the cytochrome P-450 
mixed function oxidase system, converts a relatively small proportion of 
this compound to a toxic metabolite. The toxic metabolite is capable of 
covalently binding to hepatic macromolecules and this is thought to 
cause hepatic necrosis unless it is conjugated by the tripeptide, 
glutathione (GSH). When taken in therapeutic doses, ACAP is thought to 
be one of the safest of all minor analgesics. In higher than 
recommended doses it can cause liver necrosis. As the normal 
glucuronidation and sulfation pathways are overwhelmed by excessive 
doses, more of the reactive toxic metabolite is present for GSH 
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conjugation and there is increased urinary cysteine and mercapturic acid 
excretion. As the demand for GSH exceeds the supply, the free toxic 
metabolite causes hepatotoxicity, apparently by covalently binding to 
macromolecules. 
The reactive metabolite derived from the cytochrome P-450 mixed 
function oxidase system activation of ACAP is believed to be N-acetyl-p-
benzoquinoneimine (NAPQI) (14). Several mechanisms for the formation of 
NAPQI have been proposed. Initially, it was thought that ACAP was N-
hydroxylated to form N-hydroxy-ACAP, followed by spontaneous dehydration 
to NAPQI. However, the dehydration rate seems to be too slow to support 
this proposal (15). Several alternate mechanisms of ACAP activation 
leading to NAPQI formation have been proposed which do not involve N-
hydroxy-ACAP (16,17). 
Although the identity of the toxic metabolite is generally believed 
to be NAPQI, the molecular basis for its cytotoxicity remains 
controversial. Holme et al. (18) incubated isolated rat hepatocytes 
with various concentrations of synthesized NAPQI to determine its 
cytotoxic effects. Cytotoxicity, as assessed by trypan blue exclusion 
and measurement of lactate dehydrogenase release into the medium, was 
detected 10-120 minutes after the incubation period began, with the 
longest time corresponding to the lowest NAPQI concentration. However, 
the half-life of NAPQI is so short, that less than 0.5% of the initial 
amount added could be expected to remain in the incubation medium after 
2 minutes. These authors then concluded that subsequent cellular steps 
NH.CO.CHg NH.CO.CH3 NH.CO.CH3 
[(^1 { I Acetaminophen 
4 Sulfate x/* + Glucuronic Acid 
Sulfate 
> 0 
Microsomal Mixed 
Function Oxidase 
System 
f intermediates^ 
V unknown / 
Glucuronide 
N.CO.CH, 
Postulated Acetaminophen [j ^ 
NH.CO.CH. 
Glutathione 
Toxic Metabolite |M Con|ugation 
(N-Acetyl-lmidoquinone) 11 
^ o 
Glutathione 
OH 
I 
Mercapturic Acid 
Electmphilic attac Metabolites of Acetaminophen 
nearby structures 
in hepatocyte 
Cell Necrosis 
FIGURK 1. Acetaminophen metabolism 
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must occur after the initial damage was caused by NAPQI before 
cytotoxicity could be detected. 
Support for the concept that the generalized covalent binding of 
the toxic metabolite to essential cellular macromolecules as the cause 
of cell necrosis has been provided by studies which correlate the extent 
of covalent binding with the degree of liver necrosis (19). However, 
further observations have disputed the validity of this concept. 
Devalia and McLean (20) incubated isolated rat hepatocytes with 
14 [ C]ACAP and then determined the amount of covalent binding in damaged 
and undamaged cells. After 4 hours incubation time, the undamaged cells 
contained more bound ACAP than the damaged cells contained after 1 hour. 
After 22 hours in tissue culture incubation, the undamaged cells 
"contained as much bound ACAP as the 1 hour killed cells. The authors 
suggest that covalent binding is not the main cause of ACAP induced 
hepatotoxicity, but only an initiator of a multi-step process leading to 
cell death. 
3 Genotoxicity, measured as incorporation of [ H]thymidine into 
hepatocyte DNA, was not increased after ACAP incubation in rat primary 
hepatocyte cultures (21), although significant cytotoxicity was 
observed. The toxic metabolite of ACAP seems to interact preferentially 
with proteins rather than deoxyribonucleic acid moieties. 
It has been proposed that the ACAP toxic metabolite is 
preferentially bound by particular proteins critical to the cell's 
survival. Streeter et al. (22) presented evidence for cysteine residues 
8 
as the major sites of covalent binding of ACAP in phénobarbital 
pretreated mice hepatic microsomal preparations. The ACAP toxic 
metabolite has been shown to bind covalently to GSH S-transferases if 
GSH content is depleted (23). Wendel and Cikryt (24) reported that 65% 
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of the radioactivity after [ ]ACAP was incubated with mouse liver 
homogenate, was bound to soluble protein. This radioactivity peak co-
chromatographed with GSH S-transferase activity using molecular sieve 
chromatography. This evidence suggests that the toxic metabolite is 
bound to the GSH S-transferase. Hirayama et al. (25) also provided 
evidence that GSH S-transferases are the target for binding by the ACAP 
toxic metabolite, followed by mitochondria and plasma membrane proteins. 
It has also been suggested that lipid peroxidation plays an early 
or major role in ACAP-induced hepatotoxicity. The occurrence of lipid 
peroxidation during the course of ACAP-induced cellular necrosis has 
been demonstrated (18,26-28). Malondialdehyde (MDA) production was 
observed to be dependent on GSH depletion by ACAP in mouse and rat liver 
preparations. Antioxidants, such as 2(3)-tert-butyl-4-hydroxyanisole 
(BHA) and calcium EDTA, protected mice (29) and rat (30) liver from ACAP 
induced injury. However, the incidence and extent of lipid peroxidation 
differs after treatment with carbon tetrachloride and ACAP (18). 
Recently, Fariss et al. (31) observed that there is a requirement for a-
tocopherol in the maintenance of hepatocyte viability during treatment 
with toxic chemicals. It seemed that chemically-induced cell death was 
dependent on cellular a-tocopherol rather than on the presence of 
9 
extracellular calcium as expected. They suggested that the depletion of 
a-tocopherol and GSH may be responsible for increased susceptibility to 
chemically-induced cell death. The significance of lipid peroxidation 
and cell membrane damage in the hepatotoxicity caused by ACAP remains to 
be determined. 
In subtoxic doses, a smaller fraction of ACAP is converted to the 
potentially toxic metabolite, and the sulfation and glucuronidation 
pathways predominate. Sulfate conjugation of hydroxy1 groups, either 
aliphatic, phenolic or more complex, require a continuous supply of 
inorganic sulfate to form the cosubstrate for conjugation, 
3'-phosphoadenosine- 5'-phosphosulfate (PAPS). The formation of sulfate 
conjugates from PAPS and phenolic compounds, such as ACAP, require 
catalysis by an arylsulfotransferase (E.C. 2.8.2.1.). Properties of the 
multiple forms of the arylsulfotransferases (phenol sulfotransferases of 
PST) are reviewed by Jacoby et al. (32). The control of the level and 
distribution of PST is not well understood. Mizuma et al. (33) studied 
the effects of pH, thermal treatment and the simultaneous treatment with 
p-nitrophenol on the function of PST multiple forms for ACAP sulfation 
in rat liver cytosol fraction. The sulfation rates increased with pH 
and the thermolability of the PST increased with decreasing ACAP 
concentration. They concluded that sulfation at a 1 vM ACAP 
concentration is mainly catalyzed by a thermolabile PST isozyme with a 
lower Km for ACAP, and sulfation at the higher ACAP concentration is 
catalyzed by a thermostable PST isozyme with a higher Km for ACAP. 
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The properties of uridine diphospho- (UDP) glucurcnosyl transferase 
have been reviewed by Kasper and Henton (34). Glucuronidation of ACAP 
involves the transferase and the cosubstrate, UDP-glucuronic acid 
(UDPGA). 
The regulation and induction of UDP-glucuronosyl transferase 
activity toward ACAP was studied by Hazelton and Klaassen (35). 
Pretreatment with 3-methylcholanthrene (3MC) or phénobarbital did not 
affect mouse liver UDP-glucuronosyl transferase activity toward ACAP. 
The conclusion that was drawn from these results was that the UDP-
glucuronsyl transferase activity toward ACAP could not be categorized 
as the _3MC or phénobarbital inducible forms. 
The capacity for glucuronidation has been found to be dependent on 
the concentration of the cosubstrate, UDPGA. The depletion of UDPGA by 
ACAP and the time required for recovery of UDPGA levels in rat liver 
were found to be dependent on ACAP dose (36). The amount of UDPGA 
required for conjugation of a therapeutic dose of ACAP was found to be 
almost equal to the total amount in the liver at the normal 
concentration of UDPGA. The capacity to synthesize UDPGA via the 
glucuronic acid pathway may be the limiting factor for glucuronidation 
of ACAP. 
Factors that determine the rate of sulfate or glucuronate 
conjugation include the rate at which ACAP becomes available for 
conjugation, the availability of the cosubstrate for conjugation, and 
the competition of sulfate and glucuronate for ACAP in the same cell. 
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At low doses of ACAP administration to the rat, sulfation has been shown 
to be the primary metabolic route of excretion and at higher doses, 
there is a shift to glucuronidation (37). 
In five healthy male human subjects, Clements et al. (38) found 
that the percentage of an intravenous ACAP dose excreted as the urinary 
sulfate conjugate was higher after a 5 mg/kg dose than after a 20 mg/Kg 
dose. Also, the total plasma and renal clearance of the sulfate 
conjugate was higher after the lower ACAP dose. Morris and Levy (39) 
found that 2 hours after administration of 1.5 g ACAP to adult human 
subjects, the renal clearance ratios (relative to creatinine) was 
highest for ACAP sulfate and was followed by ACAP glucuronate. The 
shift to glucuronidation at increased doses has also been demonstrated 
in the mouse. Four hours after a 150 mg/kg oral ACAP dose was 
administered to mice, the urinary glucuronate conjugate was found to be 
greater than the sulfate conjugate (40). Fischer et al. (41) also found 
a greater amount of urinary glucuronate conjugate in mice after a 500 
mg/kg oral ACAP dose. 
A similar dose-dependence of the ratio between sulfation and 
glucuronidation has been demonstrated for other substrates, including 
harmol. Mulder et al. (42) offered several explanations for this dose-
dependence, including; 1) a depletion of inorganic sulfate at the 
higher doses of the substrate, 2) differences in affinity of ACAP for 
the enzymes for sulfation and glucuronidation and 3) a non-homogenous 
distribution of the transferases and ACAP in the liver. 
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The limited availability of inorganic sulfate for incorporation 
into PAPS has been cited by some as the reason for the dose-dependence 
of the sulfation of ACAP. ACAP causes appreciable depletion of 
endogenous inorganic sulfate in animals and humans (43-50). 
Replenishment by sodium sulfate infusion increases ACAP elimination 
(44-47). PAPS concentrations have also been shown to be decreased after 
ACAP administration in rats, and serum sulfate concentration was found 
to be positively correlated (r = 0.615) with liver PAPS concentration 
(49). Sulfate in the plasma has been shown to be readily available for 
sulfation in the liver (51). Moldeus et al. (52) selectively inhibited 
sulfate and glucuronate conjugation by depleting the respective 
cofactors in vitro. However, there is also evidence that the dose-
dependence of ACAP sulfate conjugation is due only in part to inorganic 
sulfate depletion and therefore to PAPS depletion. Weitering et al. 
(53) provided evidence that although there was an Initial decrease in 
plasma sulfate after phenol doses, it was followed by a fairly rapid 
compensation, possibly by an increased supply from other body sites. 
They were able to decrease plasma sulfate only to 77% of control values 
in rats in one hour, yet one hour following 600 mg/kg ACAP i.p., others 
have shown a decrease to 30% of control (49). Mulder and Keulemans (54) 
have observed that in isolated perfused rat liver, as the inorganic 
sulfate concentration decreased, the rate of harmol sulfation decreased. 
Thev suggested that the decrease in sulfation was due to a relatively 
high Km of PAPS synthesis rather than total depletion of inorganic 
sulfate. 
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The second explanation offered for the dose dependency of ACAP 
sulfation is that the limited capacity to conjugate ACAP at high doses 
by sulfation may be a reflection of the saturation of the PST. The ACAP 
Km for sulfation is much lower than the ACAP Km for glucuronidation 
(37). This could account for the increase in ACAP sulfate conjugation 
at low ACAP concentrations and an increase in ACAP glucuronate 
conjugation at higher ACAP concentrations. When ACAP sulfation was 
suppressed by an inhibitor, such as 2,6-dichloro-4-nitrophenol, in a 
perfused rat liver preparation (55), glucuronate and GSH conjugations 
were not significantly increased. The lack of a compensatory increase 
in glucuronidation was attributed to the high Km for glucuronidation in 
relation to the ACAP concentration used. These differences in affinity 
may also be a partial explanation for the dose-dependence observed for 
ACAP conjugation by sulfate' and glucuronate. 
The third rationale offered for the dose dependency of éCAP 
sulfation involves the distribution of the conjugating enzymes in the 
liver. Pang et al. (56) provided evidence that sulfation enzymes are 
located mainly in periportal cells and glucuronidation enzymes are more 
concentrated in centrilobular cells. At low dose, the ACAP would be 
exposed first to periportal cells and when these are saturated, as in 
higher doses, the ACAP would be conjugated by glucuronate in the 
centrilobular cells. Additional study is needed to prove whether this 
hypothesis is valid for ACAP conjugation. 
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The sulfate and glucuronate conjugation pattern of harmol in rats 
in vivo was not affected by a 72 hour fast (57). However, a diet having 
48% less methionine and cysteine than the control diet, increased the 
activity of UDP-glucuronosyl transferase (58). 
The majority of the glucuronate and sulfate conjugates are 
eliminated directly by the kidney as urinary constituents. The pathways 
for disposition of the ACAP-GSH conjugate and its degradation products, 
the cysteine conjugate and the mercapturate, have been examined by Wong 
et al. (40) and Fischer et al. (59). Their results indicate that little 
of the GSH conjugate formed in the liver appears in that form in the 
urine. The ACAP-GSH conjugate is cleared from the liver via the bile, 
reabsorbed, metabolized and then excreted as the cysteine or 
mercapturate conjugates in the urine. Fischer et al. (59) found that 
the conversion of the ACAP-cysteine conjugate to the mercapturate 
occurred in the intestine and the kidney. Grafstrom et al. (60) showed 
that the enzyme, T-glutamyItranspeptidase, is present in rat intestine 
and that the conversion of the GSH conjugate from bile to the cysteine 
form occurs during reabsorption from the intestine. 
Other aspects of ACAP metabolism are species, sex and age 
differences and the circadian rhythm found in susceptibility to ACAP 
toxicity. Davis et al. (19) demonstrated that the incidence and 
severity of ACAP induced liver necrosis was greater in Golden Syrian 
hamsters and mice than in rats. Rats, guinea pigs and rabbits were 
relatively resistant to hepatic injury by ACAP. The excretion pattern 
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of ACAP-glucuronate and ACAP-sulfate after single oral doses differed in 
dogs and cats (61). In dogs, the ACAP-glucuronate was the principal 
urinary metabolite, while in cats the ACAP-sulfate conjugate was the 
major urinary metabolite. The ACAP-sulfate urinary concentration 
decreased in cats as the ACAP dose increased. 
The susceptibility to ACAP-induced hepatotoxicity has been assessed 
by serum glutamate-pyruvate transaminase and lactate dehydrogenase 
activity elevations and histological evaluations in neonatal (11 days) 
and young rats (19 and 33 days) (62,63). A decreased susceptibility was 
observed in neonatal rats compared with older rats. GSH depletion was 
maximal at all three ages after doses ranging from 750-1250 mg/Kg and 
14 
covalent binding of [ C]ACAP to hepatic and renal macromolecules was 
greater in the rats 11 and 19 days old. Green and Fischer (64) found 
that sex-related differences in rats were more easily demonstrated at 
lower ACAP doses. Sex-related differences in ACAP conjugate patterns 
were also reported, but not until the animals reached 60 days of age. 
Experiments with mice have demonstrated a circadian rhythm in 
hepatic GSH levels and a simultaneous effect on ACAP lethality (65,66). 
GSH levels were inversely related to ACAP lethality, with the peak 
lethality and lowest GSH concentrations observed at 6 PM, and the lowest 
lethality and peak GSH concentrations at 6 AM to 10 AM. 
16 
Methionine and Acetaminophen Disposition 
The potential for hepatocellular necrosis increases as the GSH 
content of the liver is depleted by the ACAP toxic metabolite (67,68). 
Therefore, the GSH content is critical in protection from ACAP induced 
hepatotoxicity. Accordingly, the availability of the sulfur-containing 
amino acids, which are GSH precursors, is also crucial in detoxication 
processes. 
The biochemistry of sulfur-containing amino acids has been reviewed 
recently by Cooper (69). The two pathways of methionine breakdown 
proposed by this review are the transsulfuration pathway (figure 2), and 
the transaminative pathway (figure 3). The diagrams of these pathways 
are presented from Benevenga and Egan (70), with some modification. The 
importance of the transaminative pathway versus the transsulfuration 
pathway in methionine catabolism is not known. However, it is generally 
believed that the transsulfuration pathway predominates. 
The reactions involved in the transsulfuration pathway (figure 2) 
are now well defined. These include the transfer of sulfur from 
methionine to cystathionine and then cleavage by the enzyme, g-
cystathionase (cystathionine synthase) to yield cysteine. The two 
salvage pathways for methionine illustrated in figure 2 involve the 
-methy11etrahydrofolate-homocysteine methyltransferase (mTHF-MT) and 
the betaine-homocysteine methyltransferase (BH-MT). 
The control of the transsulfuration pathway was investigated by 
Krebs et al. (71). They concluded that the levels are controlled to a 
17 
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2. METHYL TRANSFERASES (MULTIPLE ENZYMES) 
3. S-ADENOSYLHOMOCYSTEINE HYDROLASE 
4. CYSTATHIONINE SYNTHASE 
5. 7-CYSTATHIONASE 
6. CYSTEINE OXIDASES (CYTOSOL + MITOCHONDRIAL) 
7. N^-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE 
• TRANSMETHYLASE 
8. HOMOCYSTEINE-BETAINE TRANSMETHYLASE 
FIGURE 2. Transsulfuration pathway 
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19 
fine degree at the homocysteine level; when there is a deficiency of 
methionine, homocysteine is remethylated by mTHF-MT or BH-MT, and when 
methionine is present in excess, homocysteine is catabolized by the 
cystathionine synthase reaction to yield more cysteine. These 
conclusions have been confirmed by Finkelstein and Martin (72). They 
measured the utilization of homocysteine by mTHF-MT, BH-MT, and 
cystathionine synthase in a rat liver homogenate system. In livers from 
rats that had been fed a control laboratory ration, homocysteine was 
distributed so that 27" was accounted for by mTHF-MT, 27% by BH-MT, and 
46% by cystathionine synthase. For livers from rats that had been fed 
55% casein diets, an increase in transsulfuration activity was observed. 
The cystathionine synthase reaction accounted for 89% of the 
homocysteine consumed. The low protein or 3.5% casein diets caused an 
increase in BH-MT activity, an 83% reduction in cystathionine synthase 
activity, and a decrease of 55% in the utilization of homocysteine. It 
was suggested that the regulation of the pathway occurs through the 
distribution of homocysteine between competing pathways, with S-
adenosylmethionine activating cystathionine synthase. 
The evidence reported for the effect of methionine supply on the 
formation of cysteine, therefore, provides an appreciation for the 
effect of methionine supply on GSH content. The level of cysteine 
available for incorporation into GSH is the rate-limiting factor in GSH 
biosynthesis. The hepatic cysteine concentration is dependent on the 
activity of the transsulfuration pathway, dietary intake, and endogenous 
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protein turnover. The nutritional relationship of methionine and 
cysteine involves a methionine sparing effect by cysteine, part of the 
dietary requirement for methionine can be replaced by cysteine. 
GSH biochemistry has been extensively reviewed recently (73-77). 
The three amino acids in the tripeptide, GSH, are glutamate, cysteine, 
and glycine. The thiol-reduced form (GSH) greatly predominates over the 
disulf ide-oxidized form (GSSG) ; less than 5% of the total is present as 
GSSG. GSH is present in animal tissues in millimolar concentrations 
with the highest levels found in the liver. The GSH content represents 
at least 90% of total nonprotein low molecular weight thiols. In 
detoxification reactions, GSH is a substrate for GSH peroxidase and GSH 
S-transferase and acts as a radical scavenger. 
The GSH S-transferase enzyme catalyzes the binding of GSH to the 
electrophilic ACAP toxic metabolite or other activated xenobiotics. GSH 
peroxidase catalyzes the reaction which reduces hydrogen peroxide 
(H2O2), thereby protecting against oxygen toxicity from the 
generated by hepatic mitochrondrial oxygen consumption. GSH functions 
as an intracellular reductant, serves as a storage and transport form of 
cysteine, and is involved in the ï-glutamyl cycle for transport of 
certain amino acids. 
The maintenance of hepatic GSH levels is crucial because GSH has a 
broad range of vital functions. There is a balance between the rate of 
synthesis, the rate of utilization and the rate of GSH export from 
hepatocytes. 
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The synthesis of GSH is a two step process involving the 
constituent amino acid substrates and the enzymes, Jf-glutamylcysteine 
synthetase and GSH synthetase as shown in figure 4. GSH synthesis is 
regulated by feedback inhibition of ï-glutamylcysteine synthetase by 
GSH. GSSG reduction by GSSG reductase represents another source of GSH. 
Homeostasis of the hepatic GSH pool under normal conditions is 
maintained by a continuous turnover of GSH, involving synthesis and 
degradation. Degradation is accomplished by the efflux of GSH across 
sinusoidal and canalicular membranes, consumption by conjugation 
reactions, oxidation to GSSG, and enzymatic breakdown. Depletion by 
conjugation reactions can cause rapid synthesis of GSH and increased 
demand for cysteine which can be met by the highly responsive 
transsulfuration pathway. 
Glutamate + cysteine + ATP 
/'-glutamylcysteine 
synthetase 
7-glutamylcysteine + ADP + Pj 
y-Glutamylcysteine + glycine 
glutathione 
synthetase glutathione + ADP + Pj 
FIGURE 4. GSH biosynthesis 
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Hepatic cysteine content seems to be fairly constant after excess 
dietary methionine or cystine, the maximum change in cysteine content 
was from 0.1 to 0.25 ymole/gram wet liver tissue in rats (78). 
It has been suggested that there are two pools of GSH in the liver 
(79,80), which differ in turnover time. Meredith and Reed (81) studied 
the half-life of the hepatic mitochrondrial and cytoplasmic pools and 
reported that the mitochrondrial pool may represent the stable pool with 
the much longer half-life, compared with the cytoplasmic pool. 
Hepatic GSH content is also affected by fasting (82) and diurnal 
variations (65,66). The extent of GSH resynthesis after ACAP challenge 
is dependent on many complex, interactive factors, including dietary 
sulfur amino acid supply. 
The significance of the hepatic methionine level on ACAP 
disposition is apparent from the delineation of the trans sulfurât ion 
pathway which incorporates the methionine sulfur into cysteine and 
ultimately into GSH. There have been studies completed involving 
manipulations of dietary methionine and cysteine and its effect on 
hepatic GSH content. Seligson and Rotruck (12) fed diets to' rats that 
contained methionine in the range of 0 to 0.8% of the diet. Liver 
nonprotein sulfhydryl content increased with increasing dietary 
methionine. An increase in hepatic GSH content with increasing dietary 
sulfur containing amino acid content was also observed in rats by 
Glazenburg et al. (13). Hepatic GSH content was also shown to be 
increased proportionally by the amount of L-cysteine added to the diet 
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(83). Tateishi et al. (84) examined the proportion of dietary 
methionine that was incorporated into rat liver proteins or contributed 
its sulfur to yield cysteine and then GSH. The methionine was 
preferentially incorporated into liver proteins, increasing 
proportionally to dietary methionine increase. The methionine sulfur 
incorporated into GSH also increased proportionally as dietary 
methionine was increased from 0.18 to 0.54% of the diet. Finkelstein et 
al. (85) found the methionine concentration in rat liver to be 
relatively insensitive to dietary protein changes, while hepatic 
cysteine levels increased as dietary protein levels were raised. They 
concluded that the methionine concentration is maintained by various 
homeostatic mechanisms. 
The methionine requirement for rats and mice has been determined 
previously. However, recently Neale and Waterlow (86) examined 
methionine oxidation and adaptation at various methionine intake levels 
in the rat as a basis for determining the methionine requirement. They 
calculated an endogenous methionine oxidation loss of 35 mg/kg body 
weight per day, without adaptation below the weight maintenance level. 
Oxidation of sulfur amino acids is the primary source from which 
endogenous sulfate is derived. Inorganic sulfate in the diet accounts 
for a relatively small but variable portion of the endogenous sulfate. 
The effect of various dietary inorganic sulfate levels on rat liver 
inorganic sulfate concentrations was determined by Smith and Acuff (87). 
As dietary inorganic sulfate was raised from 0.0002 to 0.1%, liver 
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sulfate rose from 9.5 to 21.4 mg/g wet tissue. However, when dietary 
sulfate was increased to 0.42%, liver sulfate decreased. These findings 
led the authors to suggest that extraction of inorganic sulfate from the 
portal system may be enhanced by increasing dietary sulfate to the 
saturation level. 
Thus, dietary methionine intake is important in ACAP disposition, 
not only as a GSH precursor, but also to serve as a sulfur source for 
sulfate conjugation of the ACAP reactive metabolite. An optimum 
nutritional status is required for an animal to maximize its defense 
against ACAP induced hepatic necrosis. Optimum nutritional status 
implies an adequate dietary supply of the essential amino acid, 
methionine. 
Ethanol Ingestion and Acetaminophen Bioactivation 
ACAP is converted to its toxic metabolite by the cytochrome P-450 
dependent mixed-function oxidase (MFO) system. The activity of the MFO 
system, therefore, may determine in part the hepatotoxic potential of 
ACAP, especially when ingested in larger than recommended doses. 
Inhibition of the cytochrome P-450 mediated formation of the toxic 
metabolite of ACAP produces a protective effect. Miners et al. (88) 
reported the prevention of ACAP toxicity in mice by cysteamine, which 
was not dependent on GSH synthesis. They suggested, but provided no 
direct evidence, that the most likely mechanism of action of cysteamine 
was inhibition of the formation of the ACAP toxic metabolite by the MFO 
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system. Cysteamine and cysteine in high concentrations were found to 
decrease covalent binding of the ACAP toxic metabolite in mouse liver 
microsomal incubations by Buckpitt et al. (89). Inhibition of the 
formation of the toxic metabolite by the MFO system could have been 
responsible for the observed decrease in covalent binding. The 
possibility that reaction of, and not formation of, the toxic product 
with cell components, was inhibited was not addressed. Another example 
of prevention of ACAP induced hepatotoxicity was observed following 
pretreatment of mice with the interferon inducer poly(rl.rC) (90). 
Decreased hepatic GSH levels and depressed cytochrome P-450 levels led 
the authors to suggest that the protection provided by poly(rl.rC) was 
the result of a decrease in toxic metabolite formation, and therefore, 
decreased potency of the dose to exert its cytotoxic effect. Acute 
ethanol administration decreased ACAP induced hepatotoxicity in rats and 
baboons (91,92). It was postulated that this decrease was due to the 
inhibition of the biotransformation of ACAP. 
Induction of the cytochrome P-450 MFO system leads to increases in 
liver necrosis following overdoses of ACAP. Chronic ethanol ingestion 
potentiates the hepatic necrosis caused by ACAP in humans and laboratory 
animals (5-11). The extent of hepatic injury is reflected by increases 
in serum enzyme concentrations; serum glutamate-pyruvate transaminase 
(SGPT) and serum glutamate-oxaloacetate transaminase (SCOT), liver 
histopathology, and mortality. These results suggest that pretreatment 
with alcohol stimulates the cytochtome P-450 MFO system, which increases 
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the rate of ACAP metabolism. Studies in humans indicate that the 
clearance of ACAP from the plasma of chronic alcoholic subjects, or 
overall rate of ACAP metabolism, is increased compared with controls 
(93). However, there have been other mechanisms postulated for the 
increased hepatotoxicity of ACAP with chronic ethanol administration. 
Walker et al. (10) observed increased mortality, liver enlargement, and 
liver congestion following a toxic dose of ACAP in mice that had been 
pretreated with 10% ethanol in their drinking water for ten days. They 
suggested that the increased lethality was the result of the increased 
liver congestion and subsequent hypovolemia, and that the effect of 
ethanol on hepatocyte membranes caused the cells to be more susceptible 
to the ACAP toxic metabolite cytotoxic effects. The effect of chronic 
ethanol consumption on biliary excretion of ACAP in rats was studied by 
Vendemiale et al. (94). Biliary excretion of ACAP was depressed in the 
ethanol-fed rats and the decreases in hepatic and biliary GSH content 
following ACAP administration were greater than in pair fed control 
rats. They postulated that there are other contributions to increased 
ACAP induced liver pathology in rats fed ethanol chronically, such as 
reduced hepatic GSH levels and decreased biliary excretion. 
An advance in the understanding of the mechanism of potentiation of 
ACAP caused liver necrosis by ethanol was brought about by the 
recognition of an accessory pathway of hepatic ethanol metabolism, the 
microsomal ethanol oxidizing system (MEOS). There are three different 
metabolic systems in the liver capable of oxidizing ethanol. They 
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include alcohol dehydrogenase (ADH) in the cytosol, catalase in the 
peroxisomes, and the MEOS in the endoplasmic reticulum. Figure 5 
illustrates the MEOS catalyzed reaction employing 0^ and NADPH to 
generate water plus "active oxygen" which combines with ethanol to 
produce acetaldehyde and water. Activity levels of ADH and MEOS were 
studied in rats by Sturtevant and Garber (95). Rats maintained for 22 
weeks with 15% ethanol (v/v) in the drinking water, had a notable 
increase in MEOS activity when compared to acute or control groups. ADH 
activity levels were lower and more constant in the chronic ethanol 
group than the acute or control groups. MEOS activity is much more 
prominent after chronic ethanol feeding. 
CH^CH^OH + NADPH + H"*" CH^CHO + NADP + H^ O 
FIGURE 5. MEOS catalyzed reaction 
The MEOS shares many properties with other drug metabolizing 
enzymes, including the involvements of cytochrome P-450, NADPH, and 0^. 
The cytochrome P-450 dependency may explain the potentiation of ACAP 
hepatotoxicity by chronic ethanol administration. 
Chronic ethanol consumption results in proliferation of the smooth 
endoplasmic reticulum membranes (96,97). This has been shown by 
subfractionation of the liver and chemical measurements of the 
components of rat hepatic microsomes. Also, the increase in ethanol 
metabolism by the MEOS is concomitant with the increases in other drug 
metabolizing enzymes. 
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Recently, a unique isozyme of cytochrome P-450, the ethanol-
inducible isozyme 3a, was isolated and its catalytic activity toward 
ACAP was examined (98). Isozymes 3a, 4, and 6 were present in 
significant amounts in liver microsomes from rabbits that were given 
ethanol chronically. Isozymes 3a, 4, and 6 exhibited the greatest 
catalytic activity in a reconstituted enzyme system with ACAP as the 
substrate to form an intermediate capable of forming a conjugate with 
GSH. Phénobarbital-indueib1e isozyme 2 was inactive toward ACAP and 
isozyme 3b and 3c were 10- to 20-fold less effective than 3a, 4, or 6. 
The spectral and catalytic properties of the ethanol-inducible 
isozyme 3a were reported by Koop and Morgan (99) and Morgan et al. 
(100). Cytochrome P-450 3a was isolated from rabbit liver microsomes 
after chronic ethanol treatment. Substrate specificity was determined 
for isozymes 2, 3a, 3b, 3c, and 4. Isozyme 3a had the highest activity 
for the oxidation of ethanol and butanol and for the p-hydroxylation of 
aniline. 
Koop et al. (101) used antibodies to isozyme 3a to inhibit greater 
than 90% of the activity of purified isozyme 3a from ethanol treated 
rabbit liver microsomes, with aniline and ethanol as substrates, in a 
reconstituted system. This evidence demonstrated that isozyme 3a is 
responsible for most of the aniline hydroxylation and ethanol oxidation 
activity of microsomes from ethanol-treated rabbits. 
Two potent inhibitors of ADH, imidazole and pyrazole, also induced 
the rabbit liver microsomal ethanol-inducible cytochrome P-450 isozyme 
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3a (102). The authors postulate that the cytochrome P-450 dependent 
MEOS might serve as a supplement to ADH under in vivo conditions. 
Previous to these studies, there was much debate over the 
significance of cytochrome P-450 in the oxidation of ethanol. However, 
with the isolation, purification, and immunochemical evidence presented 
for cytochrome P-450 isozyme 3a in ethanol metabolism, the debate may be 
settled. Now, there is some question about the predominance of the 
cytochrome P-450 pathway over the hydroxyl radical-dependent pathway of 
ethanol oxidation. Krikun et al. (103) carried out studies evaluating 
the relative roles of these two pathways in catalyzing ethanol oxidation 
by microsomes from rats fed alcohol chronically and their pair-fed 
controls. They observed that each pathway accounted for about half of 
the total oxidizing activity of the microsomes, and that the activity of 
each was increased following ethanol pretreatment. They suggest that 
the ethanol-preferring cytochrome P-450 isozyme(s) actually account for 
only a small proportion of the total P-450 concentration. This was also 
indicated by Peterson et al. (8), having observed increased ACAP 
toxicity but no increase in cytochrome P-450 content in mouse liver 
following chronic ethanol consumption. 
Chronic ethanol ingestion may influence the hepatotoxicity of ACAP 
by other means than by induction of the cytochrome P-450 MFO system. 
Factors that may modify liver GSH levels are of critical importance in 
determining the extent of ACAP toxicity. Hepatic GSH content was 
significantly reduced by acute and chronic ethanol administration in 
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rats as reported by Fernandez and Videla (104). Rats that were given an 
acute ethanol dose exhibited decreases in hepatic GSH and increases in 
lipoperoxidation, as measured by MDA formation under conditions of 
maximal GSH depletion (105). In isolated hepatocytes from chow-fed 
rats, ethanol decreased GSH, and acetaldehyde above 0.05 mM also 
decreased GSH (106), indicating that acetaldehyde may be responsible for 
the observed GSH depletion by ethanol. Hassing et al. (107), 
furthermore, reported an increase in hepatic GSH after treating rats 
with ethanol for two weeks. An increase in liver GSH content was also 
seen by Harata et al. (108) in rats fed 20% ethanol as the only source 
of drinking water for four weeks. The lipid peroxide content of the 
alcohol fed rats was 1.5 times that of the control animals indicating 
that an increase in lipid peroxide content did not necessarily lead to 
GSH depletion in livers of rats chronically treated with ethanol. 
The a-anner in which ethanol is administered to the experimental 
animal may be important in research involving drug and nutrient 
interactions. Liquid diets are sometimes used involving controls which 
are pair fed with animals receiving ethanol isocalorically substituted 
for the carbohydrate source. This may lead to disruption of the normal 
eating pattern due to dietary restriction of the control groups. The 
composition of the diet may also be modified from the normal composition 
with carbohydrate providing a greater percentage of the total kcalories. 
These changes have led to alterations in enzyme activities associated 
with drug metabolism (109). 
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Dietary fat component affects the cytochrome P-450 concentration in 
the liver. Mounie et al. (110) found that cytochrome P-450 
concentration in the hepatic microsomes of rats was increased when the 
rats were fed diets rich in polyimsaturated fatty acids. Variation in 
dietary protein was also shown to affect hepatic microsomal drug 
metabolism in the rat (111) that was fed ethanol chronically. 
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SECTION I. EFFECTS OF DIETARY METHIONINE AND ETHANOL ON ACETAMINOPHEN 
HEPATOTOXICITY IN MICE 
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ABSTRACT 
The possible interactive relationship between nutritional 
compromise of acetaminophen detoxification and ethanol enhancement of 
acetaminophen hepatotoxicity was studied in mice by using a 2- x -2 
factorial design. Ethanol was administered to adult male mice at 0 or 
15% solution in the drinking water, and dietary methionine levels were 
at 54 or 100% of the requirement. After 4 weeks, a significant 
reduction in the median lethal time (LT_Q) following a high dose of 
acetaminophen was seen in the methionine-deficient groups. Methionine 
deficiency also caused a reduction in hepatic glutathione levels in the 
control group and in mice receiving sublethal doses of acetaminophen. 
PGOT levels were increased significantly by methionine deficiency but 
were markedly increased by the interaction of ethanol treatment and 
methionine deficiency. Glutathione S-transferase activity was not 
affected by any treatment combinations, and p-nitroanisole 0-demethylase 
activity and relative liver weights were not increased because of 
chronic ethanol ingestion. These findings indicate that methionine 
deficiency caused glutathione reduction, which predisposes the mouse to 
increased acetaminophen hepatotoxicity. Ethanol consumption did not 
seem to potentiate the increased hepatotoxic effects caused by 
methionine deficiency, except as indicated by PGOT activity. 
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INTRODUCTION 
The effect of hepatic damage attributed to the interaction of 
ethanol and acetaminophen is dependent upon nutritional status. 
Nutrition can be a critical influence on the liver's capacity for 
detoxification and protection from injury. In therapeutic doses, 
acetaminophen is rapidly metabolized in the liver by direct conjugation 
with UDPGA and PAPS and eliminated in the urine. However, in larger 
doses, the sulfation and glucuronidation pathways are overwhelmed, and 
acetaminophen is thought to be activated by a mixed-function oxidase 
involving cytochrome P-450 to a reactive toxic intermediate, which 
usually is complexed with reduced glutathione (GSH) within the liver to 
form the cysteine and mercapturate conjugates. Hepatotoxicity is 
enhanced if conjugation does not occur. Reactive metabolites not 
conjugated can covalently bind to liver macromolecules, leading to 
hepatic necrosis. 
Repeated ethanol administration results in enhanced acetaminophen 
metabolism to toxic intermediates by stimulation of hepatic microsomal 
enzyme activities and an increase in the content of cytochrome P-450 
(1,2). The toxicity of acetaminophen has been enhanced in experimental 
animals with ethanol as an apparent inducer of liver microsomal drug-
metabolizing enzymes (3-6). 
The maintenance of hepatic GSH concentration therefore is crucial 
for protection from acetaminophen toxicity. Glutathione concentration 
is the result of a dynamic system including conjugation, catabolic and 
35 
biosynthetic processes. Cysteine sources for incorporation into GSH 
include dietary intake, endogenous protein turnover, and the 
cystathionine pathway by which methionine can yield cysteine (7). The 
purpose of this study is to evaluate the possible interaction of dietary 
methionine deficiency and chronic ethanol consumption on acetaminophen 
toxicity and glutathione functions. 
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MATERIALS AND METHODS 
Treatment Design 
Adult male Swiss-Webster mice (Laboratory Supply Company, Inc., 
Indianapolis, IN) weighing 21-25 gm were randomly assigned to four 
treatment groups with 40 mice in each group. The animals were housed in 
plastic cages at 22°C with 12-hr light and dark cycle (6 AM-6 PM light) 
automatically maintained. The mouse was chosen as the experimental 
animal because it is more susceptible to acetaminophen hepatotoxicity 
than the rat (8). 
A 2- X -2 factorial design was used, with ethanol administered at 
levels of 0 or 15% in the drinking water and dietary methionine levels 
that provided either 54 or 100% of the mouse requirement for methionine 
(9). The methionine-deficient (M-D) diet was composed of the basal diet 
(Table 1), which was prepared with soy protein (Ralston Purina Co., St. 
Louis, MO). The isolated soy protein contributed 2.7 gm sulfur amino 
acid per 100 gm protein; or 54% of the methionine requirement, a portion 
of which is replaceable by L-cystine. The basal diet was supplemented 
with L-methionine (Grand Island Biological Co., Grand Island, NY) to 
prepare the methionine-sufficient (M-S) diet, which provided 100% of the 
methionine requirement; i.e., methionine at the 0.5% level in the diet. 
The animals were allowed free access to food and drinking water. Food 
and water consumption and body weight were recorded every third day. 
Table 1. Composition of basal diet 
Amino acid gm/100 mg mg/kg 
Ingredients % Composition of soy protein protein Vitamin mix diet 
Isolated soy 10.12 Alanine 4.2 D-blotln 0.200 
protein 
Cornstarch 36.44 Arginlne 7.5 Choline chloride 750.000 
Sucrose 36.44 Aspartic acid 11.9 Folic acid 0.450 
Cellulose 5.00 Cysteine 1.3 Niacin 22.500 
Corn oil 5.00 Glutamic acid 20.9 D-Calclum 
pantothenate 
37.500 
Safflower oil 1.00 Glycine 4.2 Pyridoxine-HCl 22.500 
Vitamin mix 1.00 Hlstidine 2,8 Riboflavin 7.500 
Mineral 5.00 Isoleucine 4.9 Thiamine-HCl 22.500 
premix^  
Total 100.00 Leucine 
Lysine 
8.2 
6.4 
Vitamin 0^ 2 
(0.1% Trituration 
with mannitol) 
0.023 
Methionine 1.4 Vitamin Dg 1.100 
Phenylallne 5.3 (Activated 
7-dehydrocholesterol) 
Proline 5.7 Vitamin E 32.000 
Serine 5.1 (DL-a-tocopherol 
acetate) 
Threonine 3.8 Vitamin A palmitate 2.200 
Tryptophan 1.4 Vitamin K 
(Menadione) 
18.000 
Tyrosine 3,9 
Valine 4.8 
^Williams-Briggs mineral premix + gm/kg of diet: ZNCO„ 0.03; Na„SeO„ 0.0027; CrCl~'6H„0 
0.0103. ^ 
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All animals were subjected to treatment conditions for 4 weeks. 
Twelve hours before sacrifice or acetaminophen injection, the 15% 
ethanol solution was replaced with distilled water. Sacrifice and 
acetaminophen administration were timed to minimize any effect on GSH 
content due to the diurnal variation in hepatic GSH concentration. 
According to Jaeger et al. (10), the maximum hepatic GSH concentration 
in rats occurs between 7 AM and 1 PM. Acetaminophen injections were 
administered between 7 and 8 AM and control animals were sacrificed 
between 7 and 8 AN. 
Median Lethal Time (LT Q^) 
The dose dependence and time relation of acetaminophen-induced 
hepatotoxicity had been assessed in a preliminary experiment by giving 
varied doses to mice that had been pretreated in the same manner. A 
lethal dose for all treatment groups within an 8- to 12-hr period was 
estimated to be 800 mg/kg body weight (BW) by recording time and 
mortality rate after that dose was given. Acetaminophen (ACAP) (Sigma 
Chemical Co., St. Louis, MO) was injected intraperitoneally (i.p.) as 
basic solution (pH 11.0) in physiological saline at a dose of 800 mg/k 
BW in ten mice from each group. The mortality time was recorded, and 
the LT_^ was calculated from linear regression lines. 
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Determination of Hepatic Glutathione Content and Enzyme Activities 
The GSH content was determined in liver from the remaining mice, 
which were divided into three groups; 1) mice that had received 100 
mg/kg BW ACAP i.p. 12 hr before sacrifice, 2) 300 mg/kg BW ACAP i.p. 1 
hr before sacrifice, and 3) from controls that had been pretreated but 
did not receive ACAP. All animals were killed by decapitation; the 
livers were removed, placed in liquid and stored at -80°C until GSH 
determination was done. The GSH analysis was done using Ellman's 
reagent (11) and the spectrophotometric method outlined by Jollow et al. 
(12). There were less than ten animals per group at the time of 
sacrifice because of mortality during the 4-week treatment period. 
Blood was collected in heparinized tubes from the mice that had 
received a 100 mg/kg BW i.p. dose of ACAP 12 hr earlier. A reagent kit 
(Sigma Chemical Co., St. Louis, MO) based on the method of Karmen (13) 
was used to determine plasma glutamic-oxaloacetic transaminase (PGOT) 
activity. 
A portion of fresh liver from control mice was retained for the 
measurement of GSH-S-transferase activity and p-nitroanisole 0-
demethylase activity. A microsomal preparation was used for the 
determination of p-nitroanisole 0-demethy1ase activity according to 
Mazel (14). The GSH-S-transferase-specific activity was measured in the 
microsomal supernatant by using the method of Booth et al. (15) and by 
adapting the AE for 1,chloro-2,4-dinitrobenzene from Habig et al. (16). 
Protein determinations were made according to the Lowry method (17). 
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Statistical Procedures 
Statistical significance for the data was assessed by median 
differences, using 95% confidence limits based on z-values (18). All 
other data were subjected to analysis of variance. Data are shown as 
the mean + SEM. 
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RESULTS 
Table 2 and Figure 1 illustrate the effects of methionine 
deficiency and ethanol consumption on food intake and growth rate. 
There was an initial weight loss during the first 3-4 days in all 
treatment groups except the M-S, 0% EtOH group. Food intake was 
constant in all groups except the M-D, 15% EtOH group, which exhibited a 
reduced intake due to an interactive effect of methionine deficiency and 
ethanol consumption (P < 0,05). Growth rate was retarded and final body 
weight was reduced due to methionine deficiency (P < 0.0001). 
Table 2. Effects of treatment conditions on food consumption and final 
body weight 
Treatment Food consumption^ Final body weight^  
condition N (gm/day) (gm) 
M-D, 0% EtOH 8 4.9 + 0.2 29.5 + 0.8 
M-S, 0% EtOH 8 4.9 + 0.1 33.9 + 0.5 
M-D, 15% EtOH 7 4.3 + 0.2 28.3 + 0.7 
M-S, 15% EtOH 7 4.9 + 0.2 34.0 + 0.9 
% < 0.05 for methionine and EtOH interaction, 
p^ < 0.0001 for methionine. 
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The LT_Q determination for all groups (Figure 2) showed that the 
LT_Q was reduced with methionine deficiency (P < 0.05). The M-S, 0% 
EtOH group seemed to have a shorter LT-Q than the M-S, 15% EtOH group, 
but this apparent protective effect of ethanol was not statistically 
significant. The effect may be real, but it is not proved by these 
data. 
The GSH content (Figure 3) was reduced under the three 
circumstances in which it was determined by methionine deficiency (P < 
0.0001 for control and 12 hr post 100 mg/kg BW i.p. ACAP and P < 0.05 
for 1 hr post 300 mg/kg BW i.p. ACAP). In the control group, chronic 
ethanol ingestion increased GSH content in the methionine sufficient 
dietary treatment (P < 0.01). A 300 mg/kg BW dose of ACAP drastically 
depleted GSH content; 1 hr post injection, levels were 20-30% that of 
controls. Twelve hours after a 100 mg/kg BW dose, GSH content was 120% 
of the levels in controls for M-D groups and only 60-75% that of 
controls for the M-S groups. The M-D control and injected groups always 
had GSH levels lower than the comparable M-S groups. 
An increase in PGOT activity (Table 3) was seen in the methionine-
deficient mice (P < 0.01); however, a more dramatic increase was seen in 
the M-D, 15% EtOH group because of the interaction of methionine 
deficiency and chronic ethanol ingestion (P < 0.05). Ethanol also 
increased PGOT activity (P < 0.05) in methionine-deficient or 
methionine-sufficient mice. 
FIGURIi 2. LT50 after 800 ing/kg BW acetaminophen administration via intraperitoneal injection 
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Table 3. PGOT activity 12 hrs after 100 mg/kg BW i.p. acetaminophen 
Treatment condition N (vmoles/min/l)^ 
M-D, 0% EtOH 6 424 + 95 
M-S, 0% EtOH 5 160 + 20 
M-D, 15% EtOH 8 1858 + 418 
M-S, 15% EtOH 7 200 ± 13 
< 0.01 for methionine. 
p^ < 0.05 for EtOH. 
""p < 0.05 for methionine and EtOH interaction. 
In controls, GSH-S-transferase activity (Table 4) was not 
significantly altered due to differences in treatment conditions when 
expressed as activity per mg protein or per g of liver. Table 5 
presents the p-nitroanisole 0-demethylase activity and the liver weight 
expressed as percentage of total body weight. Both measurements were 
found to be greater (P < 0.05) due to methionine adequacy but not 
changed by chronic ethanol consumption. 
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Table 4. Effects of treatment conditions on GSH-S-transferase activity 
without i.p. acetaminophen 
GSH-S-trans ferase 
activity^ 
Treatment condition N (umoles/min/mg protein) 
M-D, 0% EtOH 8 152.6 + 16.4 
M-S, 0% EtOH 8 141.3 + 13.9 
M-D, 15% EtOH 7 167.7 + 24.3 
M-S, 15% EtOH 7 115.3 + 12.2 
o^t significantly different. 
Table 5. Effects of treatment conditions on p-nitroanisole 0-demethylase 
activity and relative liver weights of mice without i.p. ace-
tominophen 
p-nitroanisole 
Treatment 0-demethylase activity^ Liver weight r 
condition N (umoles/hr/mg protein) body weight x 100 (%)^ 
M-D, 0% EtOH 8 0.022 + 0.002 4.8 + 0.2 
M-S, 0% EtOH 8 0.023 + 0.002 5.3 0.1 
M-D, 15% EtOH 7 0.019 0.002 4.9 + 0.3 
M-S, 15% EtOH 7 0.027 + 0.003 5.8 + 0.3 
% < 0.05 for methionine. 
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DISCUSSION 
Growth was not severely compromised by methionine deficiency. Both 
the methionine-deficient and methionine-sufficient mice fell within the 
range of average, weights for 26 inbred mouse strains compiled by Poiley 
(19), but the deficient mice did have reduced weights compared with the 
methionine-sufficient (Table 2). 
Methionine deficiency compromised survival time after treatment 
with a lethal dose of ACAP (Figure 2). Methionine-adequate groups 
showed a longer survival time or greater protection against ACAP-induced 
mortality. Although the exact mechanism of death is unknown (20), it 
seems likely that, if hepatotoxicity is decreased due to greater GSH 
stores, survival time after a lethal dose would be increased. The 
decrease in the LT-Q probably coincides with a reduction in GSH content 
for methionine-deficient animals. A direct relationship of hepatic GSH 
availability and extent of ACAP hepatotoxicity has been extensively 
documented (21,22). 
Methionine deficiency was found to be.responsible for reduced 
hepatic GSH concentrations both before and after ACAP challenge (Figure 
3). Hepatic GSH concentration was also decreased due to lowering of the 
cysteine/methionine content of the diet of the rat (23). 
The amount of drug-GSH conjugates excreted as mercapturic acids can 
exceed by several-fold the amount of GSH present in the liver before the 
drug is administered (24). This indicates that the liver is capable of 
synthesizing large amounts of GSH at a rapid rate when needed. It would 
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seem that a methionine-deficient animal would have some difficulty-
meeting the increased demand for cysteine for rapid GSH biosynthesis. 
However, the methionine-deficient ACAP-treated groups had GSH levels 
that were 120% of that of the control, and methionine-sufficient animals 
generated only 60-75% of that of control by 12 hr after a 100 mg/kg BW 
i.p. dose of ACAP. 
Control animals treated with ethanol had an increase in GSH content 
with methionine adequacy. Other researchers have shown a decrease in 
hepatic GSH content following chronic ethanol ingestion (25-27). 
However, Hassing et al. (28) found that rats receiving 36% of their 
calories as ethanol for two weeks had elevations in hepatic reduced and 
oxidized glutathione. Additional study of the mechanism for 
regeneration of the GSH'pool after stress in nutritionally compromised 
animals is needed. 
The PGOT activity was markedly increased due to the interaction of 
methionine deficiency and ethanol treatment (Table 3). This finding was 
not associated with interactive effects on GSH levels; the M-D, 15% EtOH 
group did not have the lower GSH content in any of the three treatment 
circumstances under which it was determined. However, there was an 
increase in PGOT levels attributable to methionine deficiency. 
The GSH-S-transferase activity did not respond to dietary 
methionine or ethanol treatment (Table 4). Induction of GSH transferase 
is well documented after phénobarbital administration, although other 
compounds are also inducers (29). In this case, ethanol was not 
so 
effective as an inducer of GSH-S-transferase. It also seems that 
methionine and GSH are not limiting factors in GSH-S-transferase 
activity. 
The potentiation of ACAP hepatotoxicity by chronic ethanol 
consumption has been observed in the mouse as well as the rat. Enhanced 
hepatotoxicity after chronic ethanol consumption was shown by a decrease 
in the LD.g (3,4), and increase in GOT activity (4-6), and greater GSH 
depletion after ACAP treatment than controls, which received ACAP but no 
ethanol (4,5). The proposed mechanism for the increased hepatotoxicity 
seen is enhanced production of reactive metabolite due to ethanol 
induction of cytochrome P-450 content and drug-metabolizing enzymes. 
Chronic ethanol consumption results in proliferation of smooth 
endoplasmic reticulum membrane, which is associated with a concomitant 
increase in microsomal capability for activation of drtigs such as 
isoniazid and ACAP (30). 
However, p-nitroanisole 0-demethylase activity and the relative 
liver weights of ethanol-treated mice were not greater than those of 
mice not given ethanol. These parameters differed only due to 
methionine content of the diet (Table 5) and did not provide evidence 
for induction of microsomal activation of ACAP by ethanol. The 
difference in p-nitroanisole 0-demethylase activity due to methionine 
content was more evident in the groups fed ethanol. It seems reasonable 
to propose that, since protein deficiency decreases hepatic drug-
metabolizing ability (31), methionine deficiency could have similar 
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effects, and could exert a protective effect by causing a reduction in 
the formation of the ACAP toxic metabolite. Evidence for this effect 
could not be determined from our data. 
In summary, it can be concluded that methionine deficiency caused 
GSH reduction that predisposed the mouse to increased ACAP 
hepatotoxicity and that ethanol potentiated the hepatotoxic effects of 
ACAP. 
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SECTION II. EFFECTS OF DIETARY METHIONINE AND ETHANOL ON ACETAMINOPHEN 
CONJUGATION IN MICE 
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ABSTRACT 
Adult, male Swiss-Webster mice were pair-fed an ethanol-containing 
liquid diet for 4 weeks that provided 46 or 100% of the methionine 
requirement in a 2- x -2 factorial design. Hepatic microsomal protein, 
relative liver weight, and microsomal aniline hydroxylase activity were 
increased in the ethanol-fed groups. Following a 300 mg/kg BW i.p. 
acetaminophen (ACAP) dose, serum inorganic sulfate and hepatic reduced 
glutathione (GSH) concentrations were decreased, while uridine 
diphospho-glucuronosy1 transferase activity was not changed. GSH levels 
were reduced to a greater extent in the methionine-deficient groups. 
14 
Data generated from experiments incorporating [ C]-methyl-methionine, 
35 35 [ S]-methionine, and Na^ I S]0^  into hepatic proteins did not reflect 
differences in transsulfuration activity as a result of dietary 
methionine deficiency. Endogenous hepatic methionine was decreased 
after ACAP administration. Methionine deficiency decreased the 
distribution of ACAP into the urinary sulfate conjugates, and ethanol 
consumption increased the percentage of sulfate and mercapturic acid 
conjugates formed. These results indicate that methionine deficiency 
compromises the normal pathways of ACAP disposition in the mouse and 
that chronic ethanol ingestion potentiates this compromise by increasing 
the amount of activated ACAP formed. 
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INTRODUCTION 
Acetaminophen (ACAP) ingestion imposes nutritional demands which 
primarily involve the maintenance of hepatic glutathione (GSH) levels. 
GSH is necessary for conjugation of the ACAP toxic metabolite generated 
by hepatic cytochrome P-450 dependent oxidation after larger than 
recommended doses. Induction of hepatic microsomal oxidation by ethanol 
increases the production of activated ACAP and thus, the demand for 
cysteine, the rate-limiting precursor for GSH biosynthesis. Methionine 
sulfur is donated to yield cysteine via the hepatic transsulfuration 
pathway. Sulfur-containing amino acids also serve as a source for 
sulfate for ACAP-sulfate conjugate formation. 
Dietary methionine deficiency has been associated with decreased 
hepatic GSH levels in rats (1,2). Chronic ethanol administration has 
been shown to cause increased ACAP induced hepatotoxicity in man and 
laboratory animals (3-9). The purpose of this study is to determine how 
dietary methionine inadequacy and chronic ethanol consumption interact 
to affect parameters involved in the detoxification of activated ACAP 
and the pattern of urinary ACAP conjugates formed. 
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MATERIALS AND METHODS 
Treatment Design 
Adult, male Swiss-Webster mice (Laboratory Supply Company, Inc., 
Indianapolis, IN) weighing 21-25 gm were randomly assigned to four 
groups with 12 mice in each group for each of three experiments. The 
animals were housed in hanging steel mesh cages at 22®C with a 12-hr 
light and dark cycle (6 AM - 6 PM light) automatically maintained. 
A 2- X -2 factorial design was used with two levels of dietary 
methionine (met) and two levels of ethanol (EtOH). The animals were 
pair-fed a liquid diet (Table 1) (10) for four weeks which provided the 
following levels of met and EtOH; met deficient or 46% of the mouse 
requirement for met (11) without EtOH (M-D); met sufficient or 100% of 
the requirement without EtOH (M-S); met deficient with 25% of the 
kcalories isocalorically substituted by EtOH (M-D; EtOH); and met 
sufficient with EtOH (M-S; EtOH). Food consumption was recorded daily 
and the animals were weighed weekly. 
Twelve hours before ACAP administration or sacrifice, the liquid 
diet was replaced with distilled water. ACAP injections and the 
sacrifice of the mice were always carried out between 8 AM and 9 AM to 
avoid variation due to the diurnal pattern of GSH concentration (12). 
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Table 1. Composition of the liquid diet 
Component Amount g/L 
Isolated soy protein^ 26. 25 
Dextrose  ^ 188. 00 
Cellulose powder^  10. ,00 
Safflower oil® 2. 20 
Com oilc  ^ 10, .80 
Vitamin mixture 12. 50 
Mineral mixture 10. 00 
Xanthan gum~ 2. 00 
Distiilr.d-deionized water 880, .00 
L-methionine added to M-S diets to provide 100% of requirement 
^Suppro 660, Ralston Purina Co., St. Louis, Missouri. 
T^eklad Test Diets, Madison, Wisconsin. 
^Mazola Brand, Iowa State University Food Service, Ames, Iowa. 
"^ The vitamin mix provided the following in grams/kg mixture: d-
biotin 0.02; choline chloride 75.0; folic acid 0.045; niacin 2.25; d-
calcium pantothenate 3.75; pyridoxine - HCl 2.25; riboflavin 0.75; 
thiamin-HCl 2.25; vitamin B-^2 (0.1% trituration with mannitol) 
0.0023; vitamin D3 (activated 7-dehydrocholesterol) 0.11; vitamin E 
(dl—2-tocopherol-acetate) 3.2; vitamin A palmicate 0.22; vitamin K 
(menadione) 1.8. Made to 1 kg with dextrose. 
W^illiams-Briggs mineral mix with Na2Se03, 0.055 g; ZnCO], 0.55 g; 
and CrCl3'6H20, 0.205 g added/kg mixture. 
K^eltrol, Kelco Corp., Clark, New Jersey. 
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Experiment 1. GSH, Sulfate and Enzyme Activities 
Half of the animals in each group were given 300 mg/kg BW i.p. ACAP 
(Sigma Chemical Co., St. Louis, MO) dissolved in 40% propylene 
glycol/physiological saline one hour before sacrifice. The remaining 
mice were given the vehicle only as an i.p. injection. Blood was 
collected after decapitation and centrifuged for serum inorganic sulfate 
determination according to the turbidimetric method of Berglund and 
Sorbo (13) as modified by Krijgsheld et al. (14). Hepatic GSH content 
was measured using Ellman's reagent (15) according to Jollow et al. 
(16). Liver microsomes were prepared and used for the determination of 
aniline hydroxylase activity by spectrophotometrically measuring the 
product, p-aminophenol, according to Mazel (17). Uridine diphospho-
glucuronosyl transferase (UDPGT) activity was assayed in liver 
microsomes according to the spectrophotometric method of Hollman and 
Touster (18) which measured the conjugation of p-nitrophenol. Protein 
content in all experiments was determined by the method of Lowry et al. 
(19). 
Experiment 2. In Vitro Protein Synthesis 
In the second experiment, half of the mice in each group were also 
- given 300 mg/kg BW i.p. ACAP one hour before sacrifice. Livers were 
removed, weighed and immediately placed on ice. Samples were minced and 
then homogenized with 5 strokes using a Potter-Elvehjem homogenizer with 
a teflon pestle in 4 volumes of ice-cold buffer. The homogenizing 
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buffer was of the following composition: 0.25 M sucrose, 0.25 M KCl, 
0.005 M Mg Acetate and 0.05 M Tris-HCl buffer at pH 7.6. The homogenate 
was then centrifuged at 6,900 g for 10 minutes. The post-mitochrondrial 
14 35 
supernatant (PMS) was used for L-[ C]-methyl-met, L-[ S]-met, and 
35 
Na^ SO^ incorporation into hepatic proteins according to the method of 
Nakano and Sidransky (20) with some modifications. The incubation 
system contained reagents in the following concentrations: 77 mM KCl, 
48 mM NaCl, 19.3 mM Tris-HCl (pH 7.5), 4.9 mM MgCl^ , 0.08 mM 
2-mercaptoethanol, 1.2 mM ATP, 0.88 mM GTP, 30 vg pyruvate kinase, 9.6 
mM phosphoenolpyruvate and 0.05 mM each of 18 amino acids (except sulfur 
containing amino acids). Reactions were carried out with PMS 
representing either 0.01 of 0.02 gm liver, the incubation buffer and 
14 35 
either 0.5 yCi L- Cmethyl-met (sp. act. 51 mCi/mmole), 0.25 yCi L- S-
met (sp. act. 1080 Ci/mmole) both purchased from Research Products 
International Corp., Mount Prospect, IL or 0.5 uCi Na^^^SO^ (sp. act. 
73.3 mCi/mmole) from Amersham Corp., Arlington Heights, IL. The amount 
of exogenous L-met added was kept constant in each incubation mixture. 
Incubation, protein preparation and detection measures were done 
according to Nakano and Sidransky (20) without modification. Endogenous 
free methionine and cysteine/cystine were assayed in the PMS after 
protein precipitation with equal volumes 6% sulfosalicylic acid by 
automated ion exchange amino acid analysis (Durrum D-400 Amino Acid 
Analyzer, Iowa State University Department of Biochemisty and 
Biophysics). 
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Experiment 3. Urinary ACAP Conjugates 
3 
All animals in each group were given p-[ H(G)]-hydroxyacetanilide 
(sp. act. 17.3 Ci/mmole, New England Nuclear, Boston, MA) at 150 vCi/kg 
35 
BW with ccld ACAP added to provide 300 mg/kg BW i.p. ACAP and L- S-
cysteine (sp. act. 1490 Ci/mmole, Amersham Corp., Arlington Heights, XL) 
at 67 uCi/kg BW. Exogenous cysteine was negligible compared to 
endogenous hepatic cysteine. Urine was collected over dry ice for 8 hrs 
and stored at -80°C until assayed for ACAP conjugate formation. The 
HPLC method of Howie et al. (21) was used to estimate urinary ACAP and 
its sulfate, glucuronide, and mercapturic acid conjugates with the 
following modifications. A Beckman llOA high-performance liquid 
chromatograph equipped with a Hitachi 100-10 spectrophotometric UV 
variable wavelength detector, a Beckman recorder and a Columbia Scientific 
Industries Supergrator-I integrator was used with a Gilson fraction 
collector and a Spherisorb ODS-2 lOii column (250 mm length x 4.6 mm 
I.D.). Urine was diluted 5-fold, filtered (Rainin Instrument Co., 
Wobum, MA) and a 5 ul volume was injected. A representative 
35 3 
chromatograph with S and H activity is given in Figure 1. Aliquots 
of urine were treated with 8-glucuronidase (Sigma Type VII from 
Escherichia coli) or sulfatase (Sigma, Type H-2 from Helix pomatia) to 
identify the glucuronide and sulfate conjugate peaks. The peak 
35 
remaining with S activity after sulfatase treatment was identified as 
the ACAP-mercapturic acid peak. The free ACAP peak was identified by 
comparison with reagent grade ACAP elution time and peak. 
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FIGURE 1. Representative chromatogram with corresponding sulfur-3 
and tritiun activity from 8-hr urine from mice after 
300 mg/kg BW i.p. ACAP 
64 
Statistical Procedures 
All data were subjected to analysis of variance and are presented 
as the mean ± SEM. 
RESULTS 
Pair-feeding kept the intake of all 4 groups fairly constant as 
shown in Figure 2. There was an initial decrease as ethanol was 
increased to provide from 10% to 25% of energy intake during the first 2 
weeks. The effect of dietary methionine deficiency and chronic ethanol 
consumption on weight gain is illustrated by Figure 3 and Table 2. A 
decrease in body weight was seen after the initial gradual increase in 
dietary ethanol, followed by a steady rise until the end of the 
pretreatment period. At this time, body weight was significantly lower 
in the M-D groups and was significantly less due to ethanol in the 
liquid diet. 
Experiment 1 
The results in Table 3 and Figures 4 and 5 demonstrate the effect 
of chronic ethanol consumption on parameters which may indicate 
induction of drug-metabolizing enzyme activity. Microsomal protein, 
liver weight expressed as percent BW or relative liver weight, and 
hepatic microsomal aniline hydroxylase activity were all increased 
significantly in the EtOH-consuming groups. 
Serum inorganic sulfate (Table 4) and hepatic GSH concentrations 
(Figure 6) were both decreased after ACAP administration, however only 
the GSH content was decreased in the M-D groups. ACAP administration 
had no effect on UDPGT activity, but there were decreases in activity in 
the M-D groups when expressed as change in absorbance per hour per liver 
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Table 2, Effect of diet on final body weight 
Body weight 
Treatment g&»b N 
M-D 31.56 ± 0.57 36 
M-S 34.71 ± 0.53 36 
M-D; EtOH 27.56 + 0.64 36 
M-S; EtOH 30.92 0.59 36 
< 0.0001 for met. 
p^ < 0.0001 for EtOH. 
Table 3. Effect of methionine deficiency and EtOK on hepatic protein 
content 
Mg microsomal Mg PMS supernatant 
Treatment pro/g liver^  N pro/g liver^ N 
M-D 31.32 + 1.99 12 147.81 + 2.86 10 
M-S 30.24 + 1.33 12 141.34 + 5.84 9 
M-D; EtOH 36.94 + 2.63 12 138.64 + 3.44 11 
M-S; EtOH 34.71 + 1.04 12 152.05 + 3.34 10 
p^ < 0.01 for EtOH. 
^p < 0.01 for met*EtOH. 
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and in the groups not consuming EtOH when expressed as change in 
absorbance per hour per gram of liver (Table 5). 
Table 4. Serum inorganic sulfate concentration 
Treatment mM^ N 
M-D 1.52 + 0.16 5 
M-D; ACAP 0.50 + 0.34 5 
M-S 1.31 + 0.37 5 
M-S; ACAP 0.85 + 0.28 5 
M-D; EtOH 2.32 + 0.71 4 
M-D; EtOH; ACAP 0.78 + 0.38 3 
M-S; EtOH 1.58 + 0.16 5 
M-S; EtOH; ACAP 1.23 + 0.26 5 
% < 0.01 for ACAP. 
Experiment 2 
The extent of ^^ C-methyl-met, ^ S^-met, and Na^ ^^ SO^  incorporation 
into hepatic proteins is shown in Table 6,7 and 8 respectively. The 
amount of -methyl-met incorporated represents the amount of met 
35 
directly contributing to protein synthesis, while the amount of S-met 
represents the amount of met directly involved in protein synthesis and 
the amount of met which is processed to donate its sulfur to cysteine 
^ACAP 
• NO ACAP 
M-S:EtOH;ACAP y//////////j6-
M-S;EtOH 
M-D;EtOH:ACAP V/////Ay 
M-D; EtOH l-H 
M-S;ACAP 
M-S 1—1 
M-D; ACAP W/////A^  
M-D hH 
1 1 1 1 1 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 
jj moles/g liver 
abcil 
FIGURE 6. Hepatic (JSII concentration 
%< 0.01 for met. 
p< 0.01 for ACAP. 
p^< a.05 for met*ACAP. 
p< 0.05 for EtOn*ACAP. 
Table 5. Urldlne-dlphospho-glucuionosyl transferase activity 1 hr after 300 mg/kg I.p. ACAP 
Treatment (A Abs/hr) /g liver^  /llver^  /mg microsomal pro^  N 
M-D 3.28 ± 0.13 4.23 ± 0.27 0.11 ± 0.01 6 
M-D; ACAP 2.87 ± 0.20 3.81 ± 0.44 0.09 ± 0.01 6 
M-S 2.91 + 0.12 4.36 ± 0.70 0.10 ± 0.01 6 
M-S; ACAP 2.99 ± 0.20 4.50 ± 0.86 0.10 ± 0.01 6 
M-D; EtOH 3.44 + 0.17 4.18 ± 0.37 0.10 ± 0.01 6 
M-D; EtOIl; ACAP 3.56 + 0.20 4.07 ± 0.54 0.10 ± 0.01 6 
M-S; EtOH 3.70 ± 0.27 6.08 ± 0.69 0.11 ± 0.01 6 
M-S; EtOH; ACAP 3.69 + 0.25 5.94 ± 0.73 0.10 ± 0.01 6 
p^ < 0.01 for EtOH. 
p^ < 0.01 for met. 
N^o significant differences. 
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via the transsulfuration pathway, which then also can be incorporated 
35 into proteins. The amount of Na^  SO^  incorporated may represent the 
amount of sulfate used for proteoglycan or other sulfate-requiring 
14 
compound synthesis. After subtracting the amount of C-methyl-met 
35 incorporation from the S-met incorporation, the resulting amount could 
be a reflection of the amount of met that donates its sulfur to form 
cysteine or of the activity of the transsulfuration pathway. However, 
there was no consistent pattern of decreased transsulfuration pathway 
activity seen in the M-D groups from the data generated in Experiment 2. 
^^ C-methyl-met incorporation was decreased in the M-D groups and ^ S^-met 
incorporation was decreased after ACAP administration. 
Endogenous free hepatic met (Figure 7) was significantly increased 
in the EtOH-consuming groups and was reduced after ACAP administration. 
35 
Endogenous met was used to calculate the extent of C-methyl-met and 
35 S-net incorporation while exogenous met was kept constant. There were 
no significant differences in hepatic endogenous free cysteine/cystine 
values (Table 9) as determined by automated amino acid analysis. 
Experiment 3 
Several animals from each group were used to determine dose and 
amount of radioactivity needed for later detection. The remaining 
animals were used for urine collection after a 300 mg/kg BW i.p. dose of 
ACAP (Table 10). ACAP-sulfate conjugate formation and free ACAP 
excretion was significantly increased in the M-S groups while ACAP-
Table 6. C-inethyl-metlilonLne Incorporation Into I'MS proteins 
% Incorporatloii^ '''*'^  mmoles iiunoles 
14 14 14 C radioactivity C me-met Incorp C-me-niet Incorp 
Treatment per g liver^ 'b per mg pro/hrb,c,a,e 
M-l) 0.61 + 0.07 0.623 ± 0.053 0.086 ± 0.006 
M-D; ACAP 0.69 + 0.10 0.691 ± 0.073 0.093 ± 0.010 
M-S 1.04 ± 0.14 1,118 ± 0.239 0.165 + 0.038 
M-S; ACAP 0.72 + 0.08 0.722 ± 0,095 0.099 + 0.009 
M-D; EtOH 0.53 ± 0.06 0.566 ± 0,046 0.084 ± 0.009 
M-D; EtOH; ACAP 0.64 + 0.07 0.613 ± 0.073 0.089 ± 0.012 
M-S; EtOH 0.58 + 0.06 " 0.605 ± 0.043 0.082 ± 0.007 
M-S; EtOH; ACAP 0.61 + ' 0.03 0.611 i 0.055 0.079 ± 0.007 
p^ < 0.05 for met. 
< 0.01 for Eton, 
p^ < 0.05 for met>vACAP. 
p^ < 0.06 for met. 
p^ < 0.01 for metAIÎtOU. 
35 
Table 7. S-metlilonlne Incorporation into PMS proteins 
% incorporation^  iiimoles mtnoles 
radioactivity incorp ^^ S-met incorp 
Treatment per g liver^  per ing pro/hr 
M-D 0.89 + 0.09 0.957 ± 0.095 0.131 ± 0.011 
M-D; ACAP 0.91 ± 0.09 0.956 ± 0.093 0.128 ± 0.014 
M-S 0.98 + 0.14 1.129 ± 0.145 0.163 ± 0.015 
M-S; ACAP 0.92 + 0.12. 1.025 ± 0.152 0.143 ± 0.021 
M-D; Eton 0.86 + 0.19 1.161 ± 0.187 0.169 ± 0.026 
M-1); Eton; ACAP 0.79 + 0.06 0.818 i 0.058 0.119 ± 0.010 
M-S; Eton 0.95 + 0.08 1.121 ± 0.073 0.152 ± 0.011 
M-S; Eton; ACAP 0.86 ± 0.14 0.930 ± 0.142 0.121 ± 0.021 
N^o significant differences, 
p^ < 0.08 for ACAP. 
p^ < 0.05 for ACAP. 
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35 
Table 8. Na^  SO^  incorporation into PMS proteins 
% incorporation^  
35 S radioactivity 
Treatment 
M-D 0.16 + 0.03 
M-D; ACAP 0.16 + 0.04 
M-S 0.21 0.03 
M-S; ACAP 0.24 + 0.08 
M-D; EtOH 0.21 + 0.05 
M-D; EtOH; ACAP 0.13 0.03 
M-S; EtOH 0.22 0.07 
M-S; EtOH; ACAP 0.23 + 0.04 
p^ < 0.08 for met. 
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Table 9. Hepatic free cystine 
Treatment nmoles/g liver^  N 
M-D 217.8 + 29.8 5 
M-D; ACAP 151.5 + 24.0 5 
M-S 137.4 + 28.1 4 
M-S; ACAP 178.3 + 32.7 5 
M-D; EtOH 191.4 + 21.4 5 
M-D; EtOH; ACAP 172.8 + 5.4 5 
M-S; EtOH 207.9 + 54.0 5 
M-S; EtOH; ACAP 147.5 + 18.9 5 
N^o significant differences. 
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glucuronate formation was decreased in the M-S groups. There was 
greater ACAP-sulfate and ACAP-mercapturic acid conjugate formation in 
the EtOH consuming groups and less ACAP-glucuronate conjugate formation 
and less free ACAP excreted in the EtOH consuming groups. 
Table 10. ACAP conjugates In 8-hr urine after 300 nig/kg BW i.p. ACAP 
Percent distribution of recovered dose 
Treatment ACAP-sulfate^ ''' ACAP-glucuronlde®»^  Free ACAP^ »^  ACAP-mercapturate^  N 
M-D 11.58 ± 0.34 71.54 + 1.19 2.45 ± 0.30 12.86 ± 0.84 9 
M-S 14.77 + 1.19 65.63 ± 2.37 3.66 ± 0.44 13.96 + 1.06 10 
M-D; Eton 14.91 ± 0.83 64.14 ± 1.41 1.26 ± 0.16 17.38 ± 1.00 7 
MS; EtOH 16.67 ± 0.65 60.87 + 1.07 1.97 ± 0.32 17.70 + 0.37 10 
p^ < 0.01 for Met. 
p^ < 0.01 for EtOH. 
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DISCUSSION 
Methionine-deficient mice and EtOH-consuming mice had a lower 
body weight than similar methionine-adéquate control animals at the end 
of the pretreatment period even though pair-feeding kept caloric intake 
fairly constant. The M-D diet contained approximately 0.225% met which 
is 45% of the 0.5% met requirement. In young adult rats (360 gm), 
Seligson and Rotruck (2) showed weight loss after being fed a diet 
providing met at 0.2% of the diet for 28 days. Rats fed a diet 
containing 0.3% met gained weight but optimal weight gain occurred with 
met at 0.5% of the diet. Glazenburg et al. (1) also saw growth 
retardation as the level of dietary sulfur from met and cysteine was 
reduced in rats. 
Hepatic microsomal changes have been seen in laboratory animals 
after chronic EtOH consumption. A proliferation of smooth endoplasmic 
reticulum is seen with a concomitant increase in the activity of some 
microsomal drug-metabolizing enzymes (22). Aniline hydroxylase activity 
(Figure 5) is clearly induced by EtOH consumption. The increased 
relative liver weight (Figure 4) is also good evidence for EtOH 
induction in EtOH consuming groups. 
A reduction in serum inorganic sulfate after ACAP administration 
has been shown by others in rats and humans (25-27) and is also shown in 
Table 4. Serum inorganic sulfate concentration was decreased compared 
to control rats after rats were fed a diet which contained 75% of the 
met level in the control diet and increased after being fed a diet 
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containing 50% of the met in the control diet for 2 weeks (1). There 
was also no clear relationship found between dietary met and serum 
inorganic sulfate in the data in Table 4, suggesting that dietary sulfur 
amino acids were not the limiting factor for serum sulfate levels. 
Hepatic GSH content was decreased as expected by met deficiency and 
as reported previously in mice and rats (1,2,28). GSH concentration was 
also predictably decreased after ACAP injections in animals fed both met 
levels, but to a greater extent in the M-D groups. The M-S mice should 
have a greater ability to protect the liver from ACAP induced necrosis. 
The enzyme that catalyzes the conjugation reaction involving ACAP 
and uridine diphospho-glucuronic acid (UDPGA), UDPGT, showed an increase 
in activity per gm of liver in the EtOH consuming groups and a decrease 
in activity per liver in the methionine-deficient groups which may 
be attributed to a decrease in liver size. Magdalou et al. 
(29) reported an increase in UDPGT activity in rats fed 
a balanced diet with only 48% of the sulfur containing amino acids of 
the control diet. Price and Jollow (30) have shown that UDPGT is not 
likely to be rate-limiting in the reaction measuring UDPGA using [ H]-
diethylstilbestrol as a substrate and guinea pig liver microsomes as the 
source of UDPGT. 
In the second experiment, radiolabelled met was incorporated into 
hepatic proteins in vitro to examine the activity of the 
transsulfuration pathway and how it is affected by treatment conditions. 
Finkelstein and Martin (31) followed the consumption of homocysteine 
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using rat liver homogenates from rats fed a standard chow diet. The 
remethylation enzymes, betaine-homccysteine methyltransferase (BH-MT) 
and methionine synthase or methyl-tetrahydrofolatehomocysteine 
methyltransferase (mTHF-MT) accounted for 53% of the homocysteine 
consumed while the cystathionine synthase reaction accounted for 46% of 
the homocysteine consumed. The percentage transsulfuration as seen by 
increases in cystathionine synthase catalysis rose to 89% after rats 
were fed a diet with excess protein, and was reduced by 83% in rats fed 
a protein deficient diet. 
M-D mice would be expected to have less transsulfuration activity, 
while ACAP-treated mice would be expected to have greater 
transsulfuration activity because of the need for a rapid increase in 
cysteine concentration to serve as a substrate for GSH biosynthesis. 
However, an increase was not observed after calculating the amount of 
met that donates its sulfur to form cysteine from the incorporation data 
in Table 6, 7, and 8, as reflected in relative incorporation rates for 
-methyl-met, ^ S^-met and Na^ ^^ SO^  into PMS proteins. The 
14 incorporation of C-methyl-met was decreased in the M-D groups which 
may indicate that an attempt was being made to conserve met for the 
35 transsulfuration pathway. The amount of S-met being incorporated is 
less after ACAP which may indicate that the met is donating its sulfur 
to cysteine which is then conserved for GSH biosynthesis rather than for 
protein synthesis. 
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Hepatic met values (Figure 7) are in agreement with those of 
Finkelstein et al. (32). These authors found that by feeding rats an 
increasing amount of dietary protein, met content of liver increased. 
No significant difference occurred due to dietary met in the data in 
Figure 7 ; however hepatic met content was decreased after ACAP 
injections, suggesting that met was contributing to the cysteine 
synthesis and GSH for ACAP conjugation. However, this is not likely 
since hepatic cysteine/cystine levels were not changed after ACAP. 
In experiment 3, the percent distribution of ACAP into sulfate 
conjugates was decreased in the N-D groups. There also was a greater 
percentage of sulfate and mercapturic acid conjugates formed in the EtOH 
consuming groups. Glazenburg et al. (1) reported a decrease in ACAP-
sulfate when dietary met was lowered, but did not show a compensatory 
increase in ACAP-glucuronate as is seen in the data in Table 11. The 
effect of chronic EtOH consumption seems to be to increase ACAP 
conjugation by sulfate or GSH and to decrease the amounts converted to 
the glucuronate or excreted as free ACAP. EtOH increases the amount of 
ACAP converted to the toxic intermediate which may account for the 
increase in ACAP-mercapturic acid excretion. There is also a greater 
decrease in GSH concentration after ACAP in the EtOH consuming groups. 
In summary, dietary met deficiency caused decreases in body weight, 
14 hepatic GSH content, C-methyl-met incorporated into hepatic proteins 
and ACAP conjugated by sulfation. Ethanol consumption resulted in 
14 decreases in body weight and C-methyl-met incorporated into hepatic 
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proteins, induction of hepatic drug-metabolizing enzymes, higher 
endogenous free hepatic met, and increased ACAP conjugated by sulfation 
and mercapturic acid formation. ACAP administration decreased serum 
35 inorganic sulfate concentration, hepatic GSH content, S-met 
incorporation into hepatic proteins, and hepatic- free methionine 
content. The interaction of EtOH consumption and met deficiency caused 
a larger decrease in protein in the PMS fraction of liver and an 
increase in the met content of the liver. 
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SUMMARY AND DISCUSSION 
By using the factorial design, the effects of dietary methionine 
deficiency and ethanol consumption on ACAP metabolism can be determined 
separately or together as possible interactive effects. Dietary 
methionine deficiency decreased hepatic glutathione 
concentrations and ACAP conjugation by sulfation, although serum 
inorganic sulfate concentration was not altered by dietary methionine 
content. Chronic ethanol consumption caused induction of the cytochrome 
P-450 dependent MFO system as shown by increased p-hydroxylation of 
aniline and increased relative liver weights. In the first paper, the 
p-nitroanisole 0-demethylase activity was not increased by 15% ethanol 
in the drinking water. This may be because ethanol may specifically 
induce only the form of cytochrome P-450 (isozyme 3a) involved in 
aniline hydroxy1ation and ACAP metabolism (98,101). Ethanol ingestion 
also resulted in increased ACAP conjugated by GSH to form mercapturic 
acid. Hepatic GSH depletion, degree of covalent binding and mercapturic 
acid conjugate excretion after large ACAP doses correlate with hepatic 
necrosis but should only be used as indices of ACAP activation and not 
of hepatotoxicity. 
Measures of hepatotoxicity used were PGOT activity increases and 
lethality determined by the LT-^ . PGOT activity was greatly increased 
by the interaction of chronic ethanol consumption and methionine 
deficiency. The LT^  ^was reduced and PGOT was increased in the 
methionine deficient groups indicating that the extent of GSH depletion 
was greater presumably because of already diminished concentrations. 
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The effect of dietary methionine deficiency on the hepatic 
transsulfuration pathway activity could not be determined from the data 
generated from the in vitro protein synthesis experiment. The 
transsulfuration activity would be expected to be decreased (71) in 
methionine deficient states, resulting in decreased cysteine 
concentrations and therefore, depressed GSH levels and reduced capacity 
for GSH resynthesis after ACAP. 
Optimal nutritional status for certain nutrients is required to 
maximize the ability of the animal to protect itself from ACAP induced 
hepatotoxicity. The chronic alcoholic may then be at an additional risk 
in taking ACAP because the dietary intake of high quality protein and 
other nutrients may be suboptimum. 
The potentiation of ACAP-induced hepatotoxicity by ethanol is a 
current concern of the health care profession, especially since the 
chronic alcoholic may be more likely to choose ACAP over aspirin as an 
analgesic because it isn't associated with gastric bleeding or erosions. 
The reports on the increased hepatotoxicity seen in alcoholics (5,6,7) 
have led to suggestions to replace ACAP with the N-methyl substituted 
derivative which has not produced hepatic necrosis in animals (112). A 
more effective way to inform alcoholic consumers of the possible dangers 
of taking ACAP is also advocated. Interactive effects of EtOH and met 
deficiency were observed directly in PGOT elevation after ACAP, however 
indirect effects may also be present. 
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